Effects of mindfulness-based cognitive therapy on breast cancer survivors with insomnia: A randomised controlled trial.
Yue Zhao, Jun-E Liu, F. Lewis, Zhi-Hong Nie, Hui Qiu, Jing Han, Ya-li Su, Shen-shen Yang
European Journal of Cancer Care May 19, 2020 DOI: 10.1111/ecc.13259 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractMindfulness-based cognitive therapy for insomnia (MBCT-I) reduced insomnia severity in breast cancer survivors compared with a waitlist control group. Improvements were sustained at post-intervention, 3-month, and 6-month follow-ups. Among participants with moderate or severe insomnia at baseline, 59.6% improved to no insomnia or subclinical insomnia at 6 months. Actigraphy measures showed decreased sleep onset latency and waking after sleep onset, and increased total sleep time and sleep efficiency. Mindfulness also increased more in the MBCT-I group at all follow-up points. The authors conclude that MBCT-I may be an efficacious non-pharmacologic intervention for improving sleep quality in this population.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 136 |
| Population | Breast cancer survivors |
| Duration | 8-week intervention, 6-month follow-up |
| Keywords | Medicine Psychology |
| Key finding | MBCT-I reduced insomnia severity and improved actigraphy-measured sleep in breast cancer survivors compared with a waitlist control, with effects sustained at 6-month follow-up. |
Abstract
OBJECTIVE We investigated the effects of mindfulness-based cognitive therapy on insomnia (MBCT-I) in breast cancer survivors. METHODS In total, 136 participants were allocated randomly to a MBCT-I group or a waitlist control (WLC) group. Indicators of insomnia and mindfulness were evaluated using the Insomnia Severity Index, actigraphy and the Five Facet Mindfulness Questionnaire. Data were collected at baseline (T1), post-intervention (T2), 3-month follow-up (T3) and 6-month follow-up (T4) time points. RESULTS Insomnia severity decreased significantly in the MBCT-I group, compared with the WLC group, at T2, T3 and T4 (all p < .001). We found that 59.6% of the MBCT-I group with moderate and severe insomnia improved to no insomnia and subclinical insomnia at T4 relative to T1, accounting for 7.9% and 55.3%, respectively. Compared with the WLC group, the MBCT-I group improved on actigraphy measures of sleep; they exhibited a pattern of decreased sleep onset latency and waking after sleep onset, as well as increased total sleep time and sleep efficiency. Mindfulness also increased more in the MBCT-I group than in the WLC group at T2, T3 and T4 (all p < .001). CONCLUSIONS MBCT-I may be an efficacious non-pharmacologic intervention to improve sleep quality in breast cancer survivors.